Thomas Albini, MD, identifies the limitations of the MUST trial study design and its implementation, and how these limitations affect study results and interpretation.
RETISERT® (ﬂuocinolone acetonide intravitreal implant) 0.59 mg is a corticosteroid indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.
Click here for full prescribing information on RETISERT®
®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.
Any other products/brand names are trademarks of the respective owners.
©Bausch & Lomb Incorporated. All rights reserved. RET.0036.USA.17